-
1
-
-
58149337448
-
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
-
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7272-7283
-
-
Hu-Lowe, D.D.1
Zou, H.Y.2
Grazzini, M.L.3
Hallin, M.E.4
Wickman, G.R.5
Amundson, K.6
Chen, J.H.7
Rewolinski, D.A.8
Yamazaki, S.9
Wu, E.Y.10
McTigue, M.A.11
Murray, B.W.12
Kania, R.S.13
O'Connor, P.14
Shalinsky, D.R.15
Bender, S.L.16
-
2
-
-
75549086120
-
Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
-
Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ (2010) Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 65:563-570
-
(2010)
Cancer Chemother Pharmacol
, vol.65
, pp. 563-570
-
-
Pithavala, Y.K.1
Tortorici, M.2
Toh, M.3
Garrett, M.4
Hee, B.5
Kuruganti, U.6
Ni, G.7
Klamerus, K.J.8
-
3
-
-
35448934762
-
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study
-
DOI 10.1016/S1470-2045(07)70285-1, PII S1470204507702851
-
Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975-984 (Pubitemid 47629888)
-
(2007)
Lancet Oncology
, vol.8
, Issue.11
, pp. 975-984
-
-
Rixe, O.1
Bukowski, R.M.2
Michaelson, M.D.3
Wilding, G.4
Hudes, G.R.5
Bolte, O.6
Motzer, R.J.7
Bycott, P.8
Liau, K.F.9
Freddo, J.10
Trask, P.C.11
Kim, S.12
Rini, B.I.13
-
4
-
-
50649095801
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
-
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
-
(2008)
J Clin Oncol
, vol.26
, pp. 4708-4713
-
-
Cohen, E.E.1
Rosen, L.S.2
Vokes, E.E.3
Kies, M.S.4
Forastiere, A.A.5
Worden, F.P.6
Kane, M.A.7
Sherman, E.8
Kim, S.9
Bycott, P.10
Tortorici, M.11
Shalinsky, D.R.12
Liau, K.F.13
Cohen, R.B.14
-
5
-
-
68949127256
-
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from a phase II study
-
Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 27:3836-3841
-
(2009)
J Clin Oncol
, vol.27
, pp. 3836-3841
-
-
Schiller, J.H.1
Larson, T.2
Ou, S.H.3
Limentani, S.4
Sandler, A.5
Vokes, E.6
Kim, S.7
Liau, K.8
Bycott, P.9
Olszanski, A.J.10
Von Pawel, J.11
-
6
-
-
24944453855
-
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results
-
Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483
-
(2005)
J Clin Oncol
, vol.23
, pp. 5474-5483
-
-
Rugo, H.S.1
Herbst, R.S.2
Liu, G.3
Park, J.W.4
Kies, M.S.5
Steinfeldt, H.M.6
Pithavala, Y.K.7
Reich, S.D.8
Freddo, J.L.9
Wilding, G.10
-
7
-
-
84863475823
-
Guidance for industry: Food-effect bioavailability and fed bioequivalence studies
-
US Department of Health and Human Services Food and Drug Administration (ed) Office of Training and Communications, Division of Drug Information, Rockville, HFD-240
-
US Department of Health and Human Services Food and Drug Administration (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies. In: (CDER) CfDEaR (ed) Office of Training and Communications, Division of Drug Information, Rockville, HFD-240
-
(2002)
(CDER) CfDEaR
-
-
-
8
-
-
84856533799
-
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
-
Pithavala YK, Tong W, Mount J, Rahavendran SV, Garrett M, Hee B, Selaru P, Sarapa N, Klamerus KJ (2012) Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 30:273-281
-
(2012)
Invest New Drugs
, vol.30
, pp. 273-281
-
-
Pithavala, Y.K.1
Tong, W.2
Mount, J.3
Rahavendran, S.V.4
Garrett, M.5
Hee, B.6
Selaru, P.7
Sarapa, N.8
Klamerus, K.J.9
-
9
-
-
10744228140
-
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
-
DOI 10.1016/S1053-4296(03)00031-6
-
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181 (Pubitemid 36962641)
-
(2003)
Seminars in Radiation Oncology
, vol.13
, Issue.3
, pp. 176-181
-
-
Trotti, A.1
Colevas, A.D.2
Setser, A.3
Rusch, V.4
Jaques, D.5
Budach, V.6
Langer, C.7
Murphy, B.8
Cumberlin, R.9
Coleman, C.N.10
Rubin, P.11
-
10
-
-
0032883045
-
Effects of food on clinical pharmacokinetics
-
Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213-255
-
(1999)
Clin Pharmacokinet
, vol.37
, pp. 213-255
-
-
Singh, B.N.1
-
11
-
-
45549094992
-
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients
-
Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A (2008) Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 19:275-281
-
(2008)
Anticancer Drugs
, vol.19
, pp. 275-281
-
-
Chu, Z.1
Chen, J.S.2
Liau, C.T.3
Wang, H.M.4
Lin, Y.C.5
Yang, M.H.6
Chen, P.M.7
Gardner, E.R.8
Figg, W.D.9
Sparreboom, A.10
-
12
-
-
63949086668
-
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients
-
Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol 63:1049-1063
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 1049-1063
-
-
Bulitta, J.B.1
Zhao, P.2
Arnold, R.D.3
Kessler, D.R.4
Daifuku, R.5
Pratt, J.6
Luciano, G.7
Hanauske, A.R.8
Gelderblom, H.9
Awada, A.10
Jusko, W.J.11
-
13
-
-
0036155275
-
Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: Toxicity, bioavailability and the effect of food
-
Berlin J, Tutsch KD, Arzoomanian RZ, Alberti D, Binger K, Feierabend C, Dresen A, Marnocha R, Pluda J, Wilding G (2002) Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. Clin Cancer Res 8:86-94 (Pubitemid 34101462)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.1
, pp. 86-94
-
-
Berlin, J.1
Tutsch, K.D.2
Arzoomanian, R.Z.3
Alberti, D.4
Binger, K.5
Feierabend, C.6
Dresen, A.7
Marnocha, R.8
Pluda, J.9
Wilding, G.10
-
14
-
-
15244352760
-
A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation
-
DOI 10.1111/j.1365-2125.2005.02335.x
-
Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D (2005) A predictive model for exemestane pharmacokinetics/ pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol 59:355-364 (Pubitemid 40388090)
-
(2005)
British Journal of Clinical Pharmacology
, vol.59
, Issue.3
, pp. 355-364
-
-
Valle, M.1
Di, S.E.2
Jannuzzo, M.G.3
Poggesi, I.4
Rocchetti, M.5
Spinelli, R.6
Verotta, D.7
-
15
-
-
34748898279
-
Daunorubicin and daunorubicinol tissue concentrations in gastric cancer patients after local administration of a liposomal preparation
-
DOI 10.1016/j.phrs.2007.08.005, PII S1043661807001569
-
Furlanut M, de Manzoni G, Pasini F, Tasselli S, Tomezzoli A, Poz D, Franceschi L (2007) Daunorubicin and daunorubicinol tissue concentrations in gastric cancer patients after local administration of a liposomal preparation. Pharmacol Res 56:344-349 (Pubitemid 47488902)
-
(2007)
Pharmacological Research
, vol.56
, Issue.4
, pp. 344-349
-
-
Furlanut, M.1
De Manzoni, G.2
Pasini, F.3
Tasselli, S.4
Tomezzoli, A.5
Poz, D.6
Franceschi, L.7
-
16
-
-
70349388719
-
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
-
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468
-
(2009)
J Clin Oncol
, vol.27
, pp. 4462-4468
-
-
Rini, B.I.1
Wilding, G.2
Hudes, G.3
Stadler, W.M.4
Kim, S.5
Tarazi, J.6
Rosbrook, B.7
Trask, P.C.8
Wood, L.9
Dutcher, J.P.10
-
17
-
-
77951907727
-
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors
-
Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL (2010) A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 21:297-304
-
(2010)
Ann Oncol
, vol.21
, pp. 297-304
-
-
Sharma, S.1
Abhyankar, V.2
Burgess, R.E.3
Infante, J.4
Trowbridge, R.C.5
Tarazi, J.6
Kim, S.7
Tortorici, M.8
Chen, Y.9
Robles, R.L.10
-
18
-
-
45449090215
-
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study
-
Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371:2101-2108
-
(2008)
Lancet
, vol.371
, pp. 2101-2108
-
-
Spano, J.P.1
Chodkiewicz, C.2
Maurel, J.3
Wong, R.4
Wasan, H.5
Barone, C.6
Letourneau, R.7
Bajetta, E.8
Pithavala, Y.9
Bycott, P.10
Trask, P.11
Liau, K.12
Ricart, A.D.13
Kim, S.14
Rixe, O.15
-
19
-
-
0032927254
-
Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications
-
Fleisher D, Li C, Zhou Y, Pao LH, Karim A (1999) Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233-254 (Pubitemid 29178760)
-
(1999)
Clinical Pharmacokinetics
, vol.36
, Issue.3
, pp. 233-254
-
-
Fleisher, D.1
Li, C.2
Zhou, Y.3
Pao, L.-H.4
Karim, A.5
|